{
    "nctId": "NCT02674204",
    "briefTitle": "STOP Heart Disease in Breast Cancer Survivors Trial",
    "officialTitle": "Statin Therapy Operates to Prevent (STOP) Heart Disease in Breast Cancer Survivors Trial",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Heart Disease, Cardiotoxicity, Myocardial Dysfunction",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2,
    "primaryOutcomeMeasure": "Change in Global Circumferential Strain (GCS) Measured by Cardiac MRI (CMRI)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients with newly diagnosed stage 1-3 breast cancer\n* Histologically confirmed HER2, ER, and PR status\n* Recommended to undergo trastuzumab treatment, with or without anthracycline. Patients will be eligible for up to 3 weeks after starting treatment.\n* Age minimum 18 years\n* Able and willing to read, understand, and sign an informed consent form (ICF) and medical release form\n* Willing and able to comply with trial protocol and follow-up\n* ECOG performance status 0-1 (Karnofsky \u2265 70%)\n\nExclusion Criteria:\n\n* Prior use of statin medication within the past year\n* Not using statin medication but is eligible for statin therapy based on the 2013 ACC/AHA guidelines (LDL cholesterol \\>190, or LDL \\<190 and ASCVD risk \\>7.5%; http://tools.acc.org/ASCVD-Risk-Estimator/) and is \\> 50 years old; or is eligible for statin therapy based on the 2013 ACC/AHA guidelines and is 40-50 years old and wishes to be placed on statin therapy\n* History of adverse effects, intolerance, or allergic reactions attributed to statin medication\n* Current use of gemfibrozil, cyclosporine, clarithromycin, itraconazole, erythromycin, the hepatitis C protease inhibitor telaprevir, HIV protease inhibitors, colchicine, or red yeast rice\n* Current use of any other investigational agent\n* Pregnant or intention to get pregnant during the next 18 months. Pregnant women are excluded from this study because atorvastatin is a lipid-lowering agent with the potential for teratogenic or abortifacient effects, and MRI is contraindicated in pregnant women.\n* History of diabetes, severe lung disease, renal disease (creatinine \\> 1.8 mg/dL or CrCl \u2264 50 mL/min), or hepatic disease (AST and ALT \\> 3 times upper normal limits)\n* Abnormal baseline echocardiogram or cardiac MRI (detection of congenital heart disease; ischemic heart disease; moderate or severe valvular heart disease; cardiomyopathy; EF \\< 55%)\n* Previously known or diagnosed heart disease (e.g. congenital; valvular; coronary artery disease; history of myocardial infarction or acute coronary syndrome; cardiomyopathy, including infiltrative, hypertensive, hypertrophic, dilated, constrictive pericarditis, or other cardiomyopathy)\n* Left ventricular dysfunction (EF \\< 55%)\n* Prior non-cardiac illness with an estimated life expectancy \\< 4 years\n* Known active infection with HIV\n* Allergy or contraindication to MRI testing, including claustrophobia, metallic parts in body the prohibiting MRI, prior gadolinium contrast reaction, or uncontrolled moderate hypertension (sitting blood pressure \\>160/95 mm Hg with measurements recorded on at least 2 occasions).\n* Has metallic breast expanders in place at the time of screening\n* Concurrent illness which in the opinion of the investigators would compromise either the patient or the integrity of the data",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}